Acta Scientific Medical Sciences (ASMS)(ISSN: 2582-0931)

Mini Review Volume 9 Issue 1

The Therapeutic Potential of Cannabidiol (CBD) Oil and ™ Zeolite Z™ in an aqueous colloidal solution of SOLergy™ Sea Minerals™ in the Prevention and Treatment of Any Cancerous Condition and Other Health Conditions

Robert Oldham Young*

Department of Research, Innerlight, Biological Research and Health Education Foundation, USA

*Corresponding Author: Robert Oldham Young, Department of Research, Innerlight, Biological Research and Health Education Foundation, USA.

Received: October 03, 2024; Published: December 06, 2024

Abstract

Cannabidiol (CBD) oil, derived from the cannabis plant, has garnered significant attention for its potential therapeutic benefits without the psychoactive effects associated with tetrahydrocannabinol (T.H.C.). This article reviews the current understanding of CBD oil, highlighting its applications in pain relief, anxiety reduction, sleep improvement, and cancer Treatment, particularly in multiple myeloma. Research indicates that CBD can enhance the efficacy of traditional cancer therapies, suggesting its role in combination treatments. MasterPeace™ Zeolite Z™ in an aqueous colloidal solution of SOLergy™ Sea Minerals™, in conjunction with CBD and T.H.C., is also discussed for its potential to remove harmful carcinogentic substances from the body. While CBD oil is generally considered safe, potential side effects and interactions with other medications warrant caution. Further research is essential to elucidate its mechanisms and therapeutic potential fully.

 Keywords: Cannabidiol; CBD Oil; Cancer Treatment; Multiple Myeloma; MasterPeace™ Zeolite Z™; SOLergy™; Sea Minerals; Detoxification; Therapeutic Benefits; Cannabinoids; Colloidal; Colloids

References

  1. Martínez V., et al. “Cannabidiol and other non-psychoactive cannabinoids for preventing and treating gastrointestinal disorders: beneficial nutraceuticals?” International Journal of Molecular Sciences9 (2020): 3067.
  2. Vučković S., et al. “Cannabinoids and Pain: New Insights from Old Molecules”. Frontiers in Pharmacology 9 (2018): 1259.
  3. Fiani B., et al. “Current application of cannabidiol (CBD) in the management and Treatment of neurological disorders”. Neurological Sciences 41 (2020): 3085-3098.
  4. Mahler G. “Cannabidiol and other phytocannabinoids as cancer therapeutics”. Pharmaceutical Medicine 2 (2022): 99-129.
  5. Dariš B., et al. “Cannabinoids in cancer Treatment: Therapeutic potential and legislation”. Bosnian Journal of Basic Medical Sciences 1 (2019): 14.
  6. Afrin F., et al. “Can hemp help? Low-THC cannabis and non-THC cannabinoids for the Treatment of Cancer”. Cancers 4 (2020): 1033.
  7. Young RO and Mansfield C A. “MasterPeace™ Zeolite Z™ Pilot StudyFound to be Safe and Effective in Removing Nano and Micro Toxic Forever Chemicals, Heavy Metals, Micro Plastics and Graphene and Aluminum Found in the Human Body Cells and Fluids”. Acta Scientific Medical Sciences9 (2024): 111-117.
  8. Nelson K M., et al. “The essential medicinal chemistry of cannabidiol (CBD)”. Journal of Medicinal Chemistry 21 (2020): 12137-12155.
  9. Casajuana Kögel C., et al. “Psychoactive constituents of cannabis and their clinical implications: a systematic review”. Adicciones 2 (2018).
  10. Rupasinghe HV., et al. “Industrial hemp (Cannabis sativa subsp. sativa) is an emerging source of value-added functional food ingredients and nutraceuticals”. Molecules18 (2020): 4078.
  11. Häuser W., et al. “Efficacy, tolerability, and safety of cannabis‐based medicines for chronic pain management-An overview of systematic reviews”. European Journal of Pain3 (2018): 455-470.
  12. CBD may interact with brain and immune system receptors to reduce inflammation and alleviate pain.
  13. Blessing EM., et al. “Cannabidiol as a Potential Treatment for Anxiety Disorders”. Neurotherapeutics4 (2015): 825-836.
  14. Devinsky O., et al. “Cannabidiol in Patients with Treatment-Resistant Epilepsy: An Open-Label Interventional Trial”. The Lancet Neurology3 (2017): 281-290.
  15. Nabissi M., et al. “Cannabinoids Synergize with Carfilzomib, Reducing Multiple Myeloma Cells Viability and Migration”. Journal of Cellular Physiology (2016).
  16. Marcu JP., et al. “Cannabidiol Enhances the Inhibitory Effects of Δ9-Tetrahydrocannabinol on Human Glioblastoma Cell Proliferation and Survival”. Molecular Cancer Therapeutics 1 (2010): 180-189.
  17. Babson K A., et al. “Cannabinoids and Sleep: A Review of the Literature.” Current Psychiatry Reports 4 (2017): 23.
  18. Van De Velde F., et al. “The Role of Cannabinoids in the Treatment of Inflammatory Bowel Disease”. Journal of Clinical Gastroenterology5 (2016): 418-426.
  19. Hasan N., et al. “Cannabis is a potential compound against various malignancies, legal aspects, and advancement by exploiting nanotechnology and clinical trials”. Journal of Drug Targeting7 (2022): 709-725.
  20. Liberati S. “The effects of cannabidiol and its synergism with bortezomib in multiple myeloma cell lines. A role for transient receptor potential vanilloid type-2”. (2014).
  21. Maina S., et al. “A systematic review of human, animal, and plant health benefits of glucosinolates and strategies for enhanced bioactivity”. Molecules16 (2020): 3682.
  22. Nabissi M., et al. “Triggering the TRPV2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents”. Carcinogenesis1 (2016): 48-57.
  23. Garcia M L and Fernandez A B. “The Role of Cannabinoids in Modulating Tumor Progression”. Journal of Experimental Clinical Cancer Research1 (2021): 174-185.
  24. Torres S., et al. “A combined preclinical therapy of cannabinoids and temozolomide against glioma”. Molecular Cancer Therapeutics1 (2011): 90-103.
  25. Ramer R and Hinz B. “Antitumorigenic targets of cannabinoids-current status and implications”. Expert Opinion on Therapeutic Targets10 (2016): 1219-1235.
  26. Caffarel MM., et al. “Δ9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation”. Cancer Research13 (2006): 6615-6621.
  27. Lin B., et al. “Cannabidiol alleviates hemorrhagic shock‐induced neural apoptosis in rats by inducing autophagy by activating the PI3K/AKT pathway”. Fundamental and Clinical Pharmacology6 (2020): 640-649.
  28. Morelli MB., et al. “The effects of cannabidiol and its synergism with bortezomib in multiple myeloma cell lines. A role for transient receptor potential vanilloid type‐2”. International Journal of Cancer11 (2014): 2534-2546.
  29. Hinz B and Ramer R. “Anti‐tumour actions of cannabinoids”. British Journal of Pharmacology10 (2019): 1384-1394.
  30. Torres S., et al. “A combined preclinical therapy of cannabinoids and temozolomide against glioma”. Molecular Cancer Therapeutics1 (2011): 90-103.
  31. Hinz B and Ramer R. “Anti‐tumour actions of cannabinoids”. British Journal of Pharmacology10 (2019): 1384-1394.
  32. Tatekawa S., et al. “Epigenetic repression of miR‐375 is the dominant mechanism for constitutive activation of the P.D.P.K. 1/RPS 6 K.A. 3 signaling axis in multiple myeloma”. British Journal of Haematology4 (2017): 534-546.
  33. Opitz BJ., et al. “The potential clinical implications and importance of drug interactions between anticancer agents and cannabidiol in patients with cancer”. Journal of Pharmacy Practice4 (2020): 506-512.
  34. Louis BW S. “Cannabis: a clinician’s guide”. C.R.C. Press (2018).
  35. Lachenmeier DW., et al. “Are adverse effects of cannabidiol (CBD) products caused by tetrahydrocannabinol (T.H.C.) contamination?” F1000 Research 8 (2019).
  36. Machado Rocha FC., et al. “Therapeutic use of Cannabis sativa on chemotherapy‐induced nausea and vomiting among cancer patients: systematic review and meta‐analysis”. European Journal of Cancer Care 5 (2008): 431-443.
  37. Young RO. "High ResolutionTransmission Electron Microscopy (HRTEM) micrograph of MasterPeace Zeolite Z (TM) in an aqueous solution of SOLergy Sea Plasma (TM)". Hikari Omni Media and Hikari Omni Research Labs all rights reserved (2024).

Citation

Citation: Robert Oldham Young. “The Therapeutic Potential of Cannabidiol (CBD) Oil and ™ Zeolite Z™ in an aqueous colloidal solution of SOLergy™ Sea Minerals™ in the Prevention and Treatment of Any Cancerous Condition and Other Health Conditions”.Acta Scientific Medical Sciences 9.1 (2025): 18-24.

Copyright

Copyright: © 2025 Robert Oldham Young. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate30%
Acceptance to publication20-30 days
Impact Factor1.403

Indexed In





Contact US